Сравнение

TB-500 vs. Thymosin Beta-4

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Заживление

Номер CAS

нет данных

77591-33-4

Молекулярная масса

888 g/mol

4921 g/mol

Период полувыведения

нет данных

Последовательность

Ac-LKKTETQ

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

Механизм действия

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Thymosin Beta-4

Thymosin Beta-4 forms a 1:1 complex with monomeric (G-)actin and is regarded as the principal actin-sequestering factor in many cell types, thereby influencing cytoskeletal dynamics and directional cell migration. Preclinical models additionally describe effects on endothelial cell migration and neovascularisation, as well as activation of survival signalling pathways (including ILK/Akt). The mechanistic evidence derives predominantly from cell-culture and animal models.

Доказательная база

Наивысшая доказательность

Модель на животных

Исследование на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	TB-500	Thymosin Beta-4
Австралия	Запрещено	—
Германия	Не одобрено	Не одобрено
США	Только для исследований	Не одобрено

Полные записи

Frequently asked questions

What is the difference between TB-500 and Thymosin Beta-4?: TB-500 is classified as "Заживление", while Thymosin Beta-4 is classified as "Заживление". TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, TB-500 or Thymosin Beta-4?: The highest available evidence level is "Модель на животных" for TB-500 and "Исследование на людях" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of TB-500 and Thymosin Beta-4 in Germany and the United States?: Германия: TB-500 — Не одобрено, Thymosin Beta-4 — Не одобрено. США: TB-500 — Только для исследований, Thymosin Beta-4 — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

TB-500

Thymosin Beta-4

Австралия

Запрещено

—

Германия

Не одобрено

США

Только для исследований

Не одобрено

Frequently asked questions

What is the difference between TB-500 and Thymosin Beta-4?

TB-500 is classified as "Заживление", while Thymosin Beta-4 is classified as "Заживление". TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, TB-500 or Thymosin Beta-4?

The highest available evidence level is "Модель на животных" for TB-500 and "Исследование на людях" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of TB-500 and Thymosin Beta-4 in Germany and the United States?

Германия: TB-500 — Не одобрено, Thymosin Beta-4 — Не одобрено. США: TB-500 — Только для исследований, Thymosin Beta-4 — Не одобрено. These are factual summaries with source and review date on the individual pages.